Department of Psychology, Qingdao Mental Health Center, Qingdao City, Shandong Province 266000, P.R. China.
Department of Pharmacy, Qingdao Women and Children's Hospital, Qingdao City, Shandong Province 266000, P.R. China.
Biosci Rep. 2018 Dec 21;38(6). doi: 10.1042/BSR20181139.
Major depressive disorder (MDD) is a common mood disorder, and the treatment of MDD requires a variety of biopsychosocial approaches. The role of Silent information regulator 1 (SIRT1) in the regulation of MDD has recently been implicated. Here, we aimed to explore and elucidate the therapeutic effects of a microRNA, miR-155, in the treatment of MDD. With quantitative real-time PCR (qRT-PCR) analysis, we confirmed that cellular and serum levels of miR-155 were up-regulated in individuals with depression compared with those in healthy controls. TargetScan analysis indicated that SIRT1 is a target of miR-155, which was confirmed by dual-luciferase assay, qRT-PCR and Western blot analyses. Treatment of human neural progenitor cells with the antidepressant drug citalopram down-regulated miR-155 expression and up-regulated SIRT1 expression. These results suggest that miR-155 is an important factor in the pathophysiology of depression. miR-155 is a potential target for the development of new antidepressant treatments.
重度抑郁症（MDD）是一种常见的情绪障碍，MDD 的治疗需要多种生物心理社会方法。沉默信息调节因子 1（SIRT1）在调节 MDD 中的作用最近已被牵涉到。在这里，我们旨在探索和阐明微小 RNA miR-155 在治疗 MDD 中的治疗效果。通过定量实时 PCR（qRT-PCR）分析，我们证实与健康对照组相比，患有抑郁症的个体的细胞和血清 miR-155 水平上调。TargetScan 分析表明 SIRT1 是 miR-155 的一个靶标，这通过双荧光素酶报告基因检测、qRT-PCR 和 Western blot 分析得到了证实。用抗抑郁药西酞普兰处理人神经祖细胞可下调 miR-155 的表达并上调 SIRT1 的表达。这些结果表明 miR-155 是抑郁症病理生理学中的一个重要因素。miR-155 是开发新的抗抑郁治疗方法的潜在靶点。
